Interacting Drugs |
Carteolol (ophthalmic) vs Calcium Channel Blockers (Nondihydropyridine) |
Security Level |
|
Mechanism |
Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers. Exceptions: Bepridil [Off Market]. |
Management |
Monitor therapy |
Carteolol (ophthalmic) vs Calcium Channel Blockers (Nondihydropyridine)
Post Review about Carteolol (ophthalmic) vs Calcium Channel Blockers (Nondihydropyridine) Click here to cancel reply.
Other Interactions of Carteolol (ophthalmic)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.